Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 4, 2008, Pages 433-445

  Lasala, John M ^a   Cox, David A ^b   Dobies, David ^c   Muhlestein, Joseph B ^d,e   Katopodis, John N ^e   Revtyak, George ^f   Baim, Donald S ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pain Specialists of Greater Lehigh Valley   (United States)

^c GENESYS REGIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e Tallahassee Research Institute   (United States)

^f INDIANA UNIVERSITY HEALTH   (United States)

^g BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Coronary disease; Drug eluting stents; Paclitaxel; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DEATH; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; PATIENT DECISION MAKING; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; Q WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; AGED; CARDIOVASCULAR DISEASE; INSTRUMENTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; STATISTICS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; UTILIZATION REVIEW;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 58149234542     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21618     Document Type: Article

References (38)

1. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
4. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-1061.
5. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, Friedman M, Baim DS, Koglin J. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007;115:2842-2847.
6. Abizaid A, Chan C, Lim YT, Kaul U, Sinha N, Patel T, Tan HC, Lopez-Cuellar J, Gaxiola E, Ramesh S, et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry). Am J Cardiol 2006;98:1028-1032.
7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
8. Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: Results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:32-36.
9. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
10. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009.
11. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000.
12. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, Abbott JD, Lee JS, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008;358:342-352.
13. Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, et al. Long-term safety and efficacy of drug-eluting stents: Two-year results of the REAL (Registro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 2007;115:3181-3188.
14. Simonton CA, Brodie B, Cheek B, Krainin F, Metzger C, Hermiller J, Juk S, Duffy P, Humphrey A, Nussbaum M, et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: Results from a large prospective multicenter registry - STENT group. J Am Coll Cardiol 2007;50:1214-1222.
15. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357:1393-1402.
16. Carrozza JP Jr, Drug-eluting stents - pushing the envelope beyond the labels? N Engl J Med 2008;358:405-407.
17. Honda Y, Fitzgerald PJ. Stent thrombosis: An issue revisited in a changing world. Circulation 2003;108:2-5.
18. Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, van Es GA, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J 2006;151:1194-1204.
19. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174-2183.
20. Leavitt BJ, Sheppard L, Maloney C, Clough RA, Braxton JH, Charlesworth DC, Weintraub RM, Hernandez F, Olmstead EM, Nugent WC, et al. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation 2004;110(11, Suppl 1):II41-II44.
21. Szabo Z, Hakanson E, Svedjeholm R. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2002;74:712-719.
22. King SB III, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the emory angioplasty versus surgery trial (EAST). J Am Coll Cardiol 2000;35:1116-1121.
23. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999;67:1045-1052.
24. Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551-2556.
25. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 2006;97:1478-1481.
26. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28:26-32.
27. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients the EVASTENT matched-cohort registry. J Am Coll Cardiol 2007; 50:501-508.
28. Daemen J, Tsuchida K, Stefanini GG, Vaina S, Kukreja N, De Jaegere PPT, Ong AT, van Domburg RT, Serruys PW. Two-year clinical follow-up of the unrestricted use of the paclitaxel-eluting stent compared to the sirolimus-eluting stent as part of the Taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. EuroIntervention 2006;7:330-337.
29. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
30. Daemen J, Ong AT, Stefanini GG, Tsuchida K, Spindler H, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 2006;98:895-901.
31. Waksman R, Buch AN, Torguson R, Xue Z, Smith K, Javaid A, Chu WW, Satler LF, Kent KM, Pichard AD. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry). Am J Cardiol 2007;100: 45-51.
32. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-1441.
33. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Agostoni P, Babic R, Airoldi F, Chieffo A, Sangiorgi GM, Montorfano M, et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 2007;49:2320-2328.
34. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover Registry. Circulation 2006;114:2154-2162.
35. Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benoit A, Goy JJ. Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: The TAXi-LATE trial. Catheter Cardiovasc Interv 2007;70:163-166.
36. Biondi-Zoccai GG, Sangiorgi GM, Antoniucci D, Grube E, Di Mario C, Reimers B, Tamburino C, Agostoni P, Cosgrave J, Colombo A. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study. Int J Cardiol 2007;117:349-354.
37. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
38. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.